# OnCo record ventana-pd-l1-sp263 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:Drug ;
onco:kind "drug" ;
schema:identifier "ventana-pd-l1-sp263" ;
schema:name "VENTANA PD-L1 (SP263) Assay"@en ;
schema:description "The VENTANA SP263 assay is an immunohistochemistry stain that measures PD-L1 on tumour cells. Approved in 2017 alongside durvalumab in bladder cancer, it became the companion test in 2021 for adjuvant atezolizumab in resected lung cancer with PD-L1 on at least 1% of tumour cells, and it agrees closely with 22C3, so laboratories often validate it as a single platform."@en ;
schema:url ;
schema:dateModified "2026-09-10"^^xsd:date ;
schema:citation ;
onco:status "approved" ;
onco:tag "test" ;
onco:modality "PD-L1 immunohistochemistry companion diagnostic assay" ;
schema:alternateName "VENTANA PD-L1 (SP263)" ;
onco:approval "US 2017: Complementary PD-L1 assay for durvalumab in urothelial carcinoma", "US 2021: Companion diagnostic for adjuvant atezolizumab in PD-L1 TC ≥1% resected NSCLC", "EU 2017: CE-IVD with claims for several PD-1/PD-L1 antibodies" ;
onco:cancers , , ;
onco:technologies , ;
onco:targets ;
onco:drugs , ;
onco:companies ;
onco:terms , ;
onco:keyPapers .